Name
ICD-O-2 Morphology
ICD-O-3 Morphology
Effective
2001 and later
Reportable
for cases diagnosed
2001 and later
Primary Site(s)
C421
Primary site must be bone marrow (C421)
Coding Manual:
Hematopoietic Coding Manual (PDF)
Abstractor Notes
People with RA with ring sideroblasts are similar to those with refractory anemia except that many of the red blood cells in the bone marrow contain characteristic ring-shaped iron deposits which are called ring sideroblasts.
The principle sites of involvement are the peripheral blood and bone marrow.
For MDS diseases (9980, 9982, 9983, 9985, 9986, 9989, 9991, 9992,9993), abstracting each of the subtypes would result in over-counting of the diseases.
1. Code only the first subtype that is diagnosed.
2. Do not change the histology code or create a new abstract for any subsequent specific MDS subtypes.
Hematologic Transplant and/or Endocrine Procedures treatments include bone marrow and stem cell transplants.
The principle sites of involvement are the peripheral blood and bone marrow.
For MDS diseases (9980, 9982, 9983, 9985, 9986, 9989, 9991, 9992,9993), abstracting each of the subtypes would result in over-counting of the diseases.
1. Code only the first subtype that is diagnosed.
2. Do not change the histology code or create a new abstract for any subsequent specific MDS subtypes.
Hematologic Transplant and/or Endocrine Procedures treatments include bone marrow and stem cell transplants.
Diagnostic Confirmation
This is a histology for which the Definitive Diagnostic Method does not include Genetics Data or Immunophenotyping, thus Diagnostic Confirmation should never be 3. If genetics and/or immunophenotyping are available, re-review to see if a more specific neoplasm can be coded.
Grade
Not Applicable
Module Rule
None
Alternate Names
Acquired idiopathic sideroblastic anemia
MDS-RS
MDS-RS-SLD
Myelodysplastic syndrome with ring sideroblasts, NOS
Myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis
RARS
Refractory anemia with hemochromatosis
Refractory anemia with ring sideroblasts associated with marked thrombocytosis
Refractory anemia with ringed sideroblasts
Refractory anemia with ring sideroblasts, NOS
Refractory anemia with sideroblasts
Definition
The peripheral blood may contain a minor population of hypochromic cells but will not show blasts. The bone marrow aspirate smear shows an increase in erythroid precursors with erythroid lineage dysplasia.
> or equal to 15% ringed sideroblasts in marrow
< 5% myeloblasts in marrow, not in blood
Erythroid dysplasia
> or equal to 15% ringed sideroblasts in marrow
< 5% myeloblasts in marrow, not in blood
Erythroid dysplasia
Definitive Diagnostic Methods
Bone marrow biopsy
Peripheral blood smear
Genetics Data
None
Immunophenotyping
None
Treatments
Chemotherapy
Hematologic Transplant and/or Endocrine Procedures
Immunotherapy
Transformations to
Transformations from
None
Same Primaries
Corresponding ICD-9 Codes
238.72 Low grade myelodysplastic syndrome lesions
Corresponding ICD-10 Codes
D46.1 Refractory anemia with sideroblasts
Corresponding ICD-10-CM Codes (U.S. only)
D46.1 Refractory anemia with sideroblasts (effective October 01, 2015)
Signs and Symptoms
Easy bruising or bleeding
Petechiae (flat, pinpoint spots under the skin caused by bleeding)
Shortness of breath
Skin paler than usual
Weakness or feeling tired
Diagnostic Exams
Progression and Transformation
~1-2% of cases evolve to acute myeloid leukemia
Epidemiology and Mortality
Age: 60-73 years median age
Incidence: 3-11% of MDS cases
Sex: no male or female predominance
Survival: 69-108 months median survival
Sources
Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J (Eds):
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (Revised 4th edition)
IARC: Lyon 2017
Section: Myelodysplastic syndromes
Pages: 109-111
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (Revised 4th edition)
IARC: Lyon 2017
Section: Myelodysplastic syndromes
Pages: 109-111
International Classification of Diseases for Oncology, Third Edition, Second Revision. Geneva: World Health Organization, 2020.
Section: ICD-O-3.2 (2020) Morphological Codes
Pages: http://www.iacr.com.fr/index.php?option=com_content&view=category&layout=blog&id=100&Itemid=577
Section: ICD-O-3.2 (2020) Morphological Codes
Pages: http://www.iacr.com.fr/index.php?option=com_content&view=category&layout=blog&id=100&Itemid=577
National Cancer Institute
Section: General Information About Myelodysplastic Syndromes
Pages: https://www.cancer.gov/types/myeloproliferative/patient/myelodysplastic-treatment-pdq
Section: General Information About Myelodysplastic Syndromes
Pages: https://www.cancer.gov/types/myeloproliferative/patient/myelodysplastic-treatment-pdq